TNFSF10 and diabetes mellitus: In this context, recombinant TRAIL treatment has been shown to ameliorate streptozotocin-induced diabetes in mice by reducing hyperglycemia, preventing catabolic manifestations such as weight loss, and partially preserving pancreatic islet morphology and residual insulin secretion [18].